



## TUMORIGENESIS AND NEOPLASTIC PROGRESSION

# miR-431 Promotes Metastasis of Pancreatic Neuroendocrine Tumors by Targeting DAB2 Interacting Protein, a Ras GTPase Activating Protein Tumor Suppressor



Tiantian Zhang,<sup>\*</sup> Soyoung Choi,<sup>\*</sup> Tuo Zhang,<sup>†</sup> Zhengming Chen,<sup>‡</sup> Yudan Chi,<sup>\*</sup> Shixia Huang,<sup>§¶</sup> Jenny Z. Xiang,<sup>†</sup> and Yi-Chieh Nancy Du<sup>\*</sup>

From the Department of Pathology and Laboratory Medicine,<sup>\*</sup> the Genomics Resources Core Facility,<sup>†</sup> and the Division of Biostatistics and Epidemiology,<sup>‡</sup> Department of Healthcare Policy and Research, Weill Cornell Medicine, New York, New York; and the Dan L. Duncan Cancer Center and Department of Molecular and Cellular Biology,<sup>§</sup> Department of Molecular and Cellular Biology,<sup>¶</sup> Baylor College of Medicine, Houston, Texas

Accepted for publication  
November 14, 2019.

Address correspondence to Yi-Chieh Nancy Du, Ph.D., 1300 York Ave., Box 69, New York, NY 10065. E-mail: [nad2012@med.cornell.edu](mailto:nad2012@med.cornell.edu).

The incidence of pancreatic neuroendocrine tumor (PNET) is increasing, and it presents with various clinical manifestations and an unfavorable survival rate. A better understanding of the drivers of PNET tumorigenesis is urgently needed. Distinct miRNA signatures have been identified for different stages of tumorigenesis in both human and mouse PNETs. The functions of these miRNAs are poorly understood. *miR-431* is the most up-regulated miRNA in the metastatic signature. However, it is unknown whether *miR-431* contributes to metastasis of PNETs. Herein, we show that *miR-431* overexpression activates Ras/extracellular signal-regulated kinase (Erk) signaling and promotes epithelial-mesenchymal transition, migration/invasion *in vitro*, and metastasis in both xenograft and spontaneous mouse models of PNET. Treatment of PNET cells with Erk inhibitor or locked nucleic acids sequestering *miR-431* inhibits invasion. Four target prediction modules and dual-luciferase reporter assays were used to identify potential mRNA targets of *miR-431*. A Ras GTPase activating protein tumor suppressor (RasGAP), DAB2 interacting protein (*DAB2IP*), was discovered as an *miR-431* target. Overexpression of *DAB2IP*'s rat homolog, but not its mutant defective in Ras GTPase activating protein activity, reverses *miR-431*'s effect on promoting invasion, Erk phosphorylation, and epithelial-mesenchymal transition of PNETs. Taken together, *miR-431* silences *DAB2IP* to activate Ras/Erk and promote metastasis of PNETs. *miR-431* may be targeted to manage metastatic PNETs. (*Am J Pathol* 2020, 190: 689–701; <https://doi.org/10.1016/j.ajpath.2019.11.007>)

Pancreatic neuroendocrine tumors (PNETs) represent one-third of gastroenteropancreatic neuroendocrine tumors and are the second malignancy of the pancreas. The 5-year survival rate is approximately 55% when the tumors are localized and resected, but only approximately 15% when the tumors are not resectable.<sup>1</sup> However, PNETs often display an indolent phenotype, resulting in late diagnosis at advanced stages when surgical resection with curative intent is no longer an alternative.<sup>2,3</sup> Sunitinib (a multitargeted protein tyrosine kinase inhibitor), everolimus (a mammalian target of rapamycin inhibitor), and lutetium Lu 177 dotatate (a radioactive peptide targeted to somatostatin receptor) are approved for the treatment of unresectable and progressive

or metastatic PNETs.<sup>2,4,5</sup> All three drugs have their limitations. Both sunitinib and everolimus only extend median survival of PNET patients by approximately 6 months, and

Supported by US Department of Defense grants W81XWH-13-1-0331 (S.C. and Y.-C.N.D.) and W81XWH-16-1-0619 (T.Z. and Y.-C.N.D.), NIH grant 1R01CA204916 (T.Z., Z.C., Y.C., and Y.-C.N.D.), Goldhirsh-Yellin Foundation (S.C. and Y.-C.N.D.), Cancer Prevention and Research Institute of Texas Proteomics and Metabolomics Core Facility Support Award RP170005 (S.H.), and National Cancer Institute Cancer Center support grant to Antibody-Based Proteomics Core/Shared Resource P30CA125123 (S.H.).

T.Z. and S.C. contributed equally to this work.  
Disclosures: None declared.

all patients developed resistance for both drugs.<sup>4,6</sup> Lutetium Lu 177 dotatate can only be used for tumors expressing somatostatin receptors. As the incidences of PNETs are increasing,<sup>7</sup> a better understanding of the mechanisms that underline PNET metastasis is vitally needed to improve therapeutic options.

miRNAs are small RNAs that regulate the expression of complementary messenger RNAs and play multiple roles in cellular functions, including cell growth, differentiation, and development.<sup>8</sup> Metastasis promoter miRNAs<sup>9</sup> and suppressor miRNAs<sup>10</sup> were first discovered in breast cancer. Subsequent studies revealed more miRNAs with functions in tumorigenesis and metastasis of other cancer types. A cross-species study of miRNAs has identified stage-specific miRNA expression signatures in human PNETs and the *RIP1-Tag2* (*RIP-Tag*) transgenic mouse model of PNETs.<sup>11</sup> Another comprehensive cross-species analysis of mRNA and miRNA transcriptomes of PNETs from the mouse model and human patients supports for the *RIP-Tag* mouse model as representative of human PNETs.<sup>12</sup> Among those miRNAs expressed in different stages of PNET tumorigenesis, *miR-431* is one of the up-regulated miRNAs in the metastasis-specific miRNA signature.<sup>11</sup> However, the role of *miR-431* during PNET tumorigenesis is unknown. In this study, we aim to determine whether *miR-431* contributes to PNET metastasis.

## Materials and Methods

### Cloning miRNA into Replication Competent Avian Leukosis Virus Long Terminal Repeat with a Splice, Bryan-Strain *Pol* Gene (RCASBP or RCABP) Vectors

RCASBP-Y-DEST has been described.<sup>13</sup> After KpnI site was added before pCMV and the first BamHI site was destroyed in pcDNA6.2 GW-*EmGFP-miR-lacZ* vector,<sup>14</sup> the pCMV-*GFP-miR-lacZ* part was subcloned from the modified pcDNA6.2 GW-*EmGFP-miR-lacZ* vector into pENTR3C using KpnI and XhoI sites. PCR-generated *miR-431* was cloned into pENTR3C-*GFP-lacZ* using *Bam*HI and *Bgl*III sites. pENTR3C-pCMV-*GFP-miR-LacZ* and pENTR3C-pCMV-*GFP-miR-431* were recombined with RCASBP-Y-DEST using LR Clonase (Invitrogen, Carlsbad, CA) to generate RCASBP-*GFP-miR-LacZ* and RCASBP-*GFP-miR-431*. Inserted regions in the new plasmids were confirmed by DNA sequencing.

### Cell Lines and Reagents

Chicken fibroblast DF1<sup>15,16</sup> and N134 cell lines<sup>17</sup> have been described. N134/*GFP-miR-LacZ* and N134/*GFP-miR-431* were generated following previously described procedure.<sup>18</sup> QGP1 cell line was kindly provided by Chris Harris (Rutgers University Cancer Institute of New Jersey, New Brunswick, NJ).<sup>19,20</sup> QGP1 cells were infected with viruses carrying thymidine kinase/green fluorescent protein (GFP)/

luciferase fusion reporter,<sup>21</sup> which was kindly provided by Drs. Inna Serganova and Ronald Blasberg (Memorial Sloan Kettering Cancer Center, New York, NY). GFP<sup>+</sup> N134/*GFP-miR-LacZ*, N134/*GFP-miR-431*, and QGP1/TGL cells were sorted using FACS-DiVa Cell Sorter (BD Biosciences, San Jose, CA) in the Weill Cornell Medicine (WCM) Flow Cytometry Core.

Rat DAB2IP expression construct, GTPase activating protein (GAP) mutant of rat DAB2IP expression construct, and the control vector (pCI-neo) were gifts from Dr. Jer-Tsong Hsieh (University of Texas Southwestern Medical Center, Dallas, TX)<sup>22</sup> and they were transiently transfected into N134/*GFP-miR-431* cells by Lipofectamine 3000 (Invitrogen) following the instructions of the manufacturer. Forty-eight hours after transfection, cells were either used for the invasion assay described below or lysed in radio-immunoprecipitation assay buffer (50 mmol/L Tris, pH 7.4, 150 mmol/L NaCl, 1% NP-40, and 0.5% sodium deoxycholate) supplemented with a protease inhibitor mixture and PhosSTOP (Roche, Pleasanton, CA) for Western blot analysis.

DF1 and N134 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 0.2 mmol/L L-glutamine, and 1% penicillin/streptomycin. QGP1 cells were cultured in RPMI-1640 medium supplemented with 10% FBS, 0.2 mmol/L L-glutamine, and 1% penicillin/streptomycin.

DNA synthesis was measured by Click-iT Plus EdU Alexa Fluor 647 Flow Cytometry Assay Kit (Invitrogen), according to the manufacturer's protocol.

Two miRCURY LNA Power miRNA inhibitors (Qiagen/Exiqon, Germantown, MD) were number 4103450102 for *has-miR-431-5p* (sequence: 5'-GCATGACGGCCTGCAA-GAC-3') and negative control A, number 199006102 (sequence: 5'-TAACACGTCTATACGCCCA-3').

### Analysis of miRNA and mRNA Expression

For miRNA analyses, total RNA was extracted from various cell lines using microRNeasy mini kit (Qiagen). miRNAs were reverse transcribed by TaqMan miRNA reverse transcription kit (number 4366596; Applied Biosystems, Foster City, CA) using 10 ng of total RNA, and the expression levels of mature miRNAs were quantified using the TaqMan miRNA expression assay (number 4427975; Applied Biosystems). Mouse *snoRNA202* and human *SNORD48* (previously known as *RNU48*) were used as endogenous controls for normalization.

For mRNA expression analyses, mRNA was isolated from cells grown on 6- or 10-cm plates using Trizol with DNase I treatment (Invitrogen) or RNeasy mini kit (Qiagen) containing genomic DNA Eliminator spin columns. Total RNA (5 µg) was reverse transcribed using cDNA First-Strand Synthesis Kit (Invitrogen), and 20 ng of the resulting cDNA was then mixed with SYBR Green PCR Master Mix (Applied Biosystems) and the appropriate primers. Each reaction was

performed in quadruplicate, and mRNA expression was quantified by performing real-time PCR amplification using an ABI Prism 7900HT Real-Time PCR System (Applied Biosystems). The primer sequences are as follows: *CDH1* (mouse, forward: 5'-CAGGTCTCCTCATGGCTTTGC-3'; reverse: 5'-CTTCCGAAAAGAAGGCTGTCC-3'), *CDH2* (mouse, forward: 5'-CATCAACCGGCTTAATGGTG-3'; reverse: 5'-ACTTTCACACGCAGGATGGA-3'), *ZEB2* (mouse, forward: 5'-ATGGCAACACATGGGTTTAGTGG C-3'; reverse: 5'-ATTGGACTCTGAGCAGATGGGTGT-3'), *SNAI2* (mouse, forward: 5'-CACATTCGAACCCACA-CATTGCCT-3'; reverse: 5'-TGTGCCCTCAGGTTT-GATCTGTCT-3'), *ACTB* (mouse, forward: 5'-ATAG GAGTCCTTCTGACCCATTCC-3'; reverse: 5'-ATGAC-GATATCGCTGCGCTGGT-3'), and *B2M* (mouse, forward: 5'-ATGCTGAAGAACGGGAAAAA-3'; reverse: 5'-CAGT CTCAGTGGGGGTGAAT-3') with the comparative  $C_T$  method ( $\Delta\Delta C_T$ ). Both *ACTB* and *B2M* were used as endogenous controls for normalization.

### Animal Experiments, Tissue Preparation, and Immunohistochemical Analysis

Generation of *RIP-Tag*; *RIP-tva* mice has been described.<sup>17</sup> Nonobese diabetic/scid-IL2Rgc knockout mice were generated by the Jackson Laboratory (Bar Harbor, ME). All mice were housed in accordance with institutional guidelines. All procedures involving mice were approved by the institutional animal care and use committee. For the experimental metastasis assay,  $1 \times 10^6$  N134 cells in 150  $\mu$ L phosphate-buffered saline were injected into the tail veins of male nonobese diabetic/scid-IL2Rgc knockout mice at the age of 7 to 8 weeks. For *in vivo* infection, viral supernatant was passed through 0.45- $\mu$ m filters and was concentrated by high-speed ultracentrifugation at  $95,400 \times g$  for 1.5 hours before intracardiac injection into *RIP-Tag*; *RIP-tva* mice at 7 weeks of age. Mice were sacrificed when they were 16 weeks of age or sick. Intracardiac injection of concentrated RCAS viruses to *RIP-Tag*; *RIP-tva* mice and viral titer determination by end-point dilution of DF1 producer cells were performed as described.<sup>17,18</sup>

Tissues were removed and fixed in 10% buffered formalin overnight at room temperature. Formalin-fixed, paraffin-embedded sections (5  $\mu$ m thick) were deparaffinized and rehydrated by passage through a graded xylene/ethanol series before staining. Hematoxylin and eosin staining was performed. Immunohistochemistry was performed using VECTASTAIN Elite ABC kit, following the manufacturer's instructions. The primary antibody used was rabbit antisynaptophysin (1:500; VP-S284; Vector Labs, Burlingame, CA).

### Active Ras Pull-Down Assay

Cells at 80% confluency from 4- to 10-cm plates were combined and lysed in 1 mL lysis buffer (25 mmol/L Tris-

HCl, pH 7.2, 150 mmol/L NaCl, 5 mmol/L MgCl<sub>2</sub>, 1% NP-40, and 5% glycerol). Of total lysate of each cell line, 6% was saved before the pull-down assay. Protein of each cell line (500  $\mu$ g) was processed with the Active Ras Pull-Down and Detection Kit (number 16117; Thermo Scientific, Waltham, MA). Activated Ras proteins were precipitated with a GST-fusion protein of the Ras-binding domain of Raf1 along with glutathione agarose resin, following the manufacturer's instruction. Precipitated proteins were eluted from beads using  $2 \times$  loading buffer (12 mmol/L Tris, pH 6.8, 5% glycerol, 0.4% SDS, 140 mmol/L 2-mercaptoethanol, and 0.02% bromophenol blue), separated by SDS-PAGE, and analyzed by Western blot analysis with anti-Ras antibody provided in the kit. The intensities of bands are quantified by Fiji software version 2.0.0-rc-41/1.40d (NIH, Bethesda, MD). The relative ratios were normalized to bands from the first lane.

### Western Blot Analysis and Immunoprecipitation

Cells were lysed in NP-40 buffer (100 mmol/L NaCl, 100 mmol/L Tris, pH 8.2, and 0.5% NP-40) supplemented with a protease inhibitor mixture and PhosSTOP (Roche). Proteins were quantified by Bradford assay (Bio-Rad, Hercules, CA). Equal amounts of proteins were separated by SDS-PAGE and transferred to nitrocellulose membranes. To visualize equal protein loading, blots were stained with Ponceau S. Blots were incubated in 5% nonfat milk in Tris-buffered saline and Tween 20, probed with primary antibodies to phosphorylated extracellular signal-regulated kinase 1/2 (p-Erk1/2; 1:1000; 4376; Cell Signaling Technology, Danvers, MA), total Erk1/2 (1:1000; 9102; Cell Signaling Technology), cadherin 1 (1:1000; 610181; BD Biosciences),  $\alpha$ -tubulin (1:1000; T5168; Sigma, St. Louis, MO), Slug (1:1000; ab27568; Abcam, Cambridge, MA), and DAB2 interacting protein (DAB2IP; 1:800; gift from Dr. Jer-Tsong Hsieh), and then incubated with horseradish peroxidase-conjugated secondary antibodies. Protein bands were visualized by enhanced chemical luminescence (Pierce, Rockford, IL).

### *In Vitro* Transwell Migration and Invasion Assay

For migration assays,  $0.5 \times 10^6$  or  $1 \times 10^6$  of cells were seeded in the upper chambers of 8- $\mu$ m porous polycarbonate membranes with DMEM containing 2% FBS, 0.2 mmol/L L-glutamine, and 1% penicillin/streptomycin. The lower chambers were filled with DMEM containing 10% FBS, 0.2 mmol/L L-glutamine, and 1% penicillin/streptomycin. After 72 hours, cells migrating to the bottom chambers were fixed, stained with 0.1% crystal violet for 30 minutes, and counted in eight fields under  $\times 10$  magnification.

For invasion assays,  $2.5$  to  $5 \times 10^4$  cells were seeded in the Matrigel-coated transwell chambers (BD Biosciences) with DMEM containing 1% FBS, 0.2 mmol/L L-glutamine, and 1% penicillin/streptomycin. The lower chambers were

filled with DMEM containing 10% FBS, 0.2 mmol/L L-glutamine, and 1% penicillin/streptomycin. After 48 hours, cells on the opposite side of the chambers were fixed with 4% paraformaldehyde for 20 minutes, stained with 0.1% crystal violet for 30 minutes, and counted in eight fields under  $\times 20$  magnification.

For SCH772984 (Selleck Chemicals LLC, Houston, TX) treatment, N134 cells were pretreated with dimethyl sulfoxide (vehicle control) or 1  $\mu\text{mol/L}$  SCH772984 for 7 days. A total of  $2.5 \times 10^4$  cells were seeded in Matrigel-coated transwell chambers with either dimethyl sulfoxide or 1  $\mu\text{mol/L}$  SCH772984 in both the upper and lower chambers.

For invasion assays of transiently transfected cells,  $10^6$  cells were seeded in the Matrigel-coated transwell chambers (BD Biosciences) with DMEM containing 1% FBS, 0.2 mmol/L L-glutamine, and 1% penicillin/streptomycin. The lower chambers were filled with DMEM containing 10% FBS, 0.2 mmol/L L-glutamine, and 1% penicillin/streptomycin. After 72 hours of incubation, cells on the opposite side of the chambers were fixed by 4% paraformaldehyde for 20 minutes, stained with 0.1% crystal violet for 30 minutes, and counted in all the fields under  $\times 20$  magnification. Experiment was conducted in triplicates. To analyze cell proliferation,  $0.5 \times 10^6$  cells were seeded directly onto 24-well plates in triplicate. After 72 hours, cells were fixed by 4% paraformaldehyde for 20 minutes, stained with 0.1% crystal violet for 30 minutes, and lysed by 500  $\mu\text{L}$  methanol with gentle shaking at the speed of 200 rpm for 20 minutes. Cell lysate from each well (200  $\mu\text{L}$ ) was transferred to a 96-well plate, and OD560 was read.

For QGP1 cell invasion assay, a control inhibitor (*LNA-CTRL*) or *miR-431* inhibitor (*LNA-miR-431*) was transfected to QGP1 cells. After 4 days,  $7.5 \times 10^4$  cells were seeded in Matrigel-coated transwell chambers. Forty-eight hours later, cells were counted as described.<sup>23</sup>

### Total RNA Extraction, RNA-Seq Analysis, and Computational Analysis

Total RNA was extracted using the RNeasy Plus mini kit (74134; Qiagen) and QIAshredder kit (79654; Qiagen), according to the manufacturer's protocol. After isolation, the total RNA integrity was checked using an Agilent Technologies (Santa Clara, CA) 2100 Bioanalyzer. cDNA libraries were generated using the Illumina TruSeq RNA Sample Preparation kit and sequenced with pair-end 51 bp on HiSeq4000 sequencer (Illumina, San Diego, CA). Tophat version 2.0.11<sup>24</sup> was used to align sequencing reads to the mm9 mouse reference genome, and Cufflinks version 2.1.1<sup>25,26</sup> was used to measure transcript abundances in fragments per kilobase of exon model per million mapped reads and to identify differentially expressed genes. The RNA-sequencing (RNA-Seq) data sets of this study are available in Gene Expression Omnibus (<https://www.ncbi.nlm.nih.gov/geo/>; accession number GSE139119). Gene set enrichment analysis was used to determine whether an a priori defined set of genes

shows statistically significant, concordant differences between N134 cells expressing *GFP-miR-431* and N134 cells expressing *GFP-miR-LacZ* (control).

### RPPA Profiling and Analysis

Reverse phase protein array (RPPA) was performed as described previously with minor modifications.<sup>27–30</sup> Protein lysates were prepared from cultured cells with modified Tissue Protein Extraction Reagent (Life Technologies, Carlsbad, CA) and a cocktail of protease and phosphatase inhibitors (Roche). The lysates were diluted into 0.5 mg/mL in SDS sample buffer and denatured on the same day. The Aushon 2470 Arrayer (Aushon BioSystems, Billerica, MA) with a 40-pin (185- $\mu\text{m}$ ) configuration was used to spot samples and control lysates onto nitrocellulose-coated slides (Grace Bio-Labs, Bend, OR) using an array format of 960 lysates/slide (2880 spots/slide). The slides were processed as described and probed with a set of 224 antibodies against total proteins and phosphoproteins using an automated slide stainer Autolink 48 (Dako, Santa Clara, CA). Each slide was incubated with one specific primary antibody, and a negative control slide was incubated with antibody diluent without any primary antibody. Primary antibody binding was detected using a biotinylated secondary antibody followed by streptavidin-conjugated IRDye680 fluorophore (LI-COR Biosciences, Lincoln, NE). Total protein content of each spotted lysate was assessed by fluorescent staining with Sypro Ruby Protein Blot Stain, according to the manufacturer's instructions (Molecular Probes, Eugene, OR).

Fluorescence-labeled slides were scanned on a GenePix 4400 AL scanner, along with accompanying negative control slides, at an appropriate photomultiplier tubes voltage setting to obtain optimal signal for this specific set of samples. The images were analyzed with GenePix Pro 7.2 (Molecular Devices, San Jose, CA). Total fluorescence signal intensities of each spot were obtained after subtraction of the local background signal for each slide and were then normalized for variation in total protein, background, and non-specific labeling using a group-based normalization method, as described.<sup>27</sup> For each spot on the array, the background-subtracted foreground signal intensity was subtracted by the corresponding signal intensity of the negative control slide (omission of primary antibody) and then normalized to the corresponding signal intensity of total protein for that spot. Each image, along with its normalized data, was evaluated for quality through manual inspection and control samples. Antibody slides that failed the quality inspection were either repeated at the end of the staining runs or removed before data reporting. Total 211 antibodies remained in the list.

### Transfection and 3' UTR Luciferase Reporter Assay

The 3' untranslated region (UTR) of mouse DAB2IP was amplified by PCR and cloned into a pmirGLO Dual-

Luciferase miRNA Target Expression Vector (Promega, Madison, WI). HEK 293T cells were cotransfected with miRNA mimic (Invitrogen) and pmirGLO Dual-Luciferase 3' UTR vector using the Lipofectamine 2000 Transfection Agent following the manufacturer's instructions (Invitrogen). Scrambled miRNA mimic (number 4464066; Invitrogen) was a control. 3' UTR mutant was a mutant form of the DAB2IP 3' UTR within the miR-431 binding site. Forty-eight hours after transfection, cells were analyzed for luciferase activity using the Dual-Glo Luciferase Assay System (Promega). QGP1 cells were transfected with pmirGLO Dual-Luciferase 3' UTR vector using Lipofectamine 3000 Transfection Agent, following the manufacturer's instructions (Invitrogen).

### Statistical Analysis

To compare the survival outcome between groups, Kaplan-Meier method was used to estimate the survival probability, followed by a log-rank test. Two-sample *t*-test was used to compare numerical outcomes. Fisher exact test was used to compare categorical outcomes. All statistical tests were two sided, with an  $\alpha$  level of 0.05 as the significance cutoff. Statistical analyses were performed in statistical software SAS version 9.4 (SAS Institute, Cary, NC).

The normalized values were used in RPPA data analysis. The three replicates of each sample were log<sub>2</sub> transformed and then averaged before analysis as a biological replicate. R package limma version 3.28.21 (<https://bioconductor.org/packages/3.2/bioc/html/limma.html>)<sup>31</sup> was used to identify the differentially expressed protein between treatment and control with a Benjamini-Hochberg false discovery rate of 0.05 as the significance cutoff.

## Results

### miR-431 Promotes Metastasis in a Spontaneous Mouse Model of PNETs *in Vivo*

We have developed a novel somatic gene transfer system using *RIP-Tag; RIP-tva* mouse model to study the function of genes in metastasis.<sup>17,18</sup> To evaluate whether miR-431 can promote PNET metastasis, the *RIP-Tag; RIP-tva* mouse model was used. RCASBP viruses encoding the cDNA for *GFP-miR-431* or *GFP-miR-LacZ* were generated. High titer virus stocks (0.1 mL; >10<sup>8</sup> infectious units per milliliter) were injected into 7-week-old *RIP-Tag; RIP-tva* mice intracardially. *RCASBP-GFP-miR-LacZ* was used as a negative control for adverse effects of viral infection per se. Nine weeks after infection, the pancreas and other organs were harvested for histologic staging and grading of the lesions. To aid the search for PNET metastases, one pancreatic tissue section per mouse was subjected to immunohistochemical staining for synaptophysin, a neuroendocrine marker. Approximately three pancreatic lymph nodes were found per pancreatic tissue section. Pancreatic


lymph node metastases were readily observed by synaptophysin staining in 7 of 20 mice (10 males and 10 females) injected with *RCASBP-GFP-miR-431*, but not in any of the control mice (six males and four females) injected with *RCASBP-GFP-miR-LacZ* (Figure 1A and Table 1). Among the seven mice that developed pancreatic lymph node metastases by *miR-431* overexpression, six of them were males. There was an increasing trend approaching significance that *miR-431* promoted more pancreatic lymph node metastasis in male *RIP-Tag; RIP-tva* mice than in female mice ( $P = 0.0573$ ; Fisher exact test).

*miR-431* group had 5.53 times higher risk of death than *miR-LacZ* control group, and the survival difference was significantly different ( $P = 0.0003$ ; log-rank test) (Figure 1B). Because PNETs in *RIP-Tag; RIP-tva* mice secreted insulin and lowered blood glucose levels, blood glucose levels of the mice were also measured as a severity of illness indicator. The nonfasting glucose levels of mice infected with *RCASBP-GFP-miR-431* were significantly lower than those of the mice injected with *RCASBP-GFP-miR-LacZ* at the end point (Figure 1C). On the other hand, the primary tumor burden of mice infected with *RCASBP-GFP-miR-431* was not significantly different from that of control mice at the end point (Figure 1D). These data suggested that *miR-431* promotes spontaneous lymph node metastasis, but not the growth of primary PNETs.

### *miR-431* Increases Migration and Invasion of PNETs *in Vitro* and Promotes PNET Metastasis in a Tail Vein Assay of Metastasis *in Vivo*

For *in vitro* studies, mouse PNET N134 cells expressing either *GFP-miR-431* or control *GFP-miR-LacZ* were generated. The expression levels of *miR-431* in these cell lines were determined by the TaqMan miRNA expression assay, and *miR-431* was increased approximately 1.5-fold in *GFP-miR-431*-expressing cells than in control *GFP-miR-LacZ*-expressing cells (Figure 2A). To examine whether *miR-431* has a role in PNET migration and invasion, *in vitro* transwell migration assays and invasion assays were used. Cell migration or invasion was measured through Matrigel along a serum gradient through the membrane for 48 or 72 hours. *GFP-miR-431*-expressing cells increased migration and invasion compared with *GFP-miR-LacZ*-expressing cells (Figure 2, B and C), suggesting that *miR-431* promotes migration and invasion of mouse PNETs.

To further investigate the metastatic effect of *miR-431 in vivo*, an experimental metastasis assay was performed. A total of 1.5 million of *GFP-miR-LacZ*-expressing N134 cells or *GFP-miR-431* cells were injected into the tail vein of male nonobese diabetic/scid-IL2Rgc knockout immunodeficient mice. Six weeks after the injection, livers of the recipient mice were harvested to survey for metastasis. The four major liver lobes of each mouse were processed into histologic section with hematoxylin and eosin staining. One section of each major liver lobe was examined for the



**Figure 1** *miR-431* promotes lymph node metastasis in the spontaneous pancreatic neuroendocrine tumor (PNET) mouse model. **A:** *RIP-Tag*; *RIP-tva* mice were infected with the indicated RCASBP retroviruses at 7 weeks of age and sacrificed at 16 weeks of age. Lymph node metastasis was only observed in mice infected with RCASBP-GFP-*miR-431*, not in mice infected with RCASBP-GFP-*miR-LacZ*. Images show representative synaptophysin staining of metastatic PNET in pancreatic lymph nodes. **B:** Kaplan-Meier survival curve for *RIP-Tag*; *RIP-tva* mice infected with RCASBP-GFP-*miR-LacZ* and RCASBP-GFP-*miR-431*. **C:** Blood glucose levels of *RIP-Tag*; *RIP-tva* mice infected with RCASBP-GFP-*miR-LacZ* and RCASBP-GFP-*miR-431* at the end point. **D:** Tumor burden of *RIP-Tag*; *RIP-tva* mice infected with RCASBP-GFP-*miR-LacZ* and RCASBP-GFP-*miR-431* at the end point. \* $P < 0.05$ , \*\*\* $P < 0.001$  versus *miR-LacZ*. Scale bars = 20  $\mu\text{m}$  (A).

presence of metastases. Although only two of seven mice receiving control *GFP-miR-LacZ*-expressing N134 cells developed metastases, and six of six mice receiving *GFP-miR-431*-expressing N134 cells developed liver metastases (Table 2 and Figure 2D). These results suggested that *miR-431* promotes metastasis of PNET cells.

To determine the effect of *miR-431* on cell proliferation, 5-ethynyl-2-deoxyuridine (EdU) assay was performed. The flow cytometric analysis of cells labeled with Alexa Fluor EDU demonstrated that *miR-431* did not significantly increase cell proliferation (Figure 2E). This was consistent with no significant change of primary tumor burden in mice infected with RCASBP-GFP-*miR-431* (Figure 1D).

### *miR-431* Increases Ras/Erk Signaling and Induces EMT of PNETs

To investigate potential pathways regulated by *miR-431* at the mRNA expression levels and the functional protein levels, RNA-Seq was performed using N134 cells expressing *GFP-miR-LacZ* (control) or *GFP-miR-431*. Gene set enrichment analysis showed that the 16 gene sets were significantly enriched at nominal  $P = 0.01$  in N134-

**Table 1** Impact of *miR-431* Overexpression on Spontaneous Metastasis of *RIP-Tag*; *RIP-tva* *In Vivo*

RCASBP-	Lymph node metastases
<i>GFP-miR-LacZ</i>	0/10 mice (0%)
<i>GFP-miR-431</i>	7/20 mice (35%)*


\* $P < 0.05$  (Fisher exact test).

GFP, green fluorescent protein; RCASBP, replication competent ALV LTR with a splice, bryan-strain pol gene.

expressing *GFP-miR-431*, five of them were oncogenic KRAS signatures, and one of them was a constitutively active MEK signature (Figure 3A and Supplemental Figure S1). To validate the effect of *miR-431* on Ras signaling activation, an active Ras pull-down assay was performed. Cell lysates were prepared from N134 cells expressing *GFP-miR-LacZ* or *GFP-miR-431* and a human pancreatic ductal adenocarcinoma (PDAC) cell line, AsPC1. AsPC1, which has an activating *KRAS*<sup>G12D</sup> mutation<sup>32</sup> and active p-Erk1/2 signaling, served as a positive control (Figure 3B). A GST-fusion protein of the Ras-binding domain of Raf1, along with glutathione agarose resin, was used to specifically pull down active Ras. Western blot analysis using an anti-Ras antibody showed higher levels of active Ras and p-Erk1/2 in *GFP-miR-431*-expressing N134 cells than in *GFP-miR-LacZ*-expressing N134 cells (Figure 3B).

Moreover, RPPA analysis, a high-throughput antibody-based technique for simultaneously measuring multiple protein expression levels, was performed.<sup>28</sup> This led to an identification of 10 differentially up-regulated proteins by *miR-431* that function in epithelial-mesenchymal transition (EMT), migration, invasion, and metastasis in N134 cells (Table 3). Among them, p-Erk was the most up-regulated protein in cells expressing *GFP-miR-431* (fold change, 5.2). It was independently verified that p-Erk levels were higher in *GFP-miR-431*-expressing N134 cells than in the control cells by Western blot analysis (Figure 3C).

It has been reported that Ras/Erk2 signaling induced EMT.<sup>33</sup> *GFP-miR-431*-expressing N134 cells were more mesenchymal-like, with up-regulation of *CDH2*, *ZEB2*, and *SNAI2* in the RNA-Seq data (Figure 3D). Real-time PCR



**Figure 2** *miR-431* facilitates pancreatic neuroendocrine tumor migration, invasion, and metastasis *in vitro* and *in vivo*. **A:** Increased levels of *miR-431* in N134/*GFP-miR-431* compared with N134/*GFP-miR-LacZ* (control). **B:** Migration of N134/*GFP-miR-LacZ* and N134/*GFP-miR-431* cells was determined using *in vitro* transwell migration chambers with a serum gradient (1% to 10%). Representative images of the migrated cells are shown. Data are expressed as the normalized number of migrated cells in the bottom chambers in eight fields under  $\times 10$  magnification after 72 hours relative to that of control cells from five independent experiments. **C:** Invasion of N134/*GFP-miR-LacZ* and N134/*GFP-miR-431* cells was determined using *in vitro* Matrigel invasion chambers with a serum gradient (1% to 10%). Representative images of the invaded cells are shown. Data are expressed as the normalized number of invaded cells in the bottom surface of chambers in eight fields under  $\times 10$  magnification after 48 hours relative to that of control cells from four independent experiments. **D:** *miR-431* increases the incidence of metastasis formation compared with *miR-LacZ* in tail vein metastasis assay in nonobese diabetic/*scid-IL2Rgc* knockout mice. Liver sections from mice injected with N134/*GFP-miR-LacZ* or N134/*GFP-miR-431* through tail vein were stained with hematoxylin and eosin. The dashed line indicates macrometastasis. **E:** Flow cytometric analysis of N134/*GFP-miR-LacZ* and N134/*GFP-miR-431* cells showing the number of proliferating [5-ethynyl-2'-deoxyuridine (EdU)-positive] cells after 1-hour treatment of 10  $\mu\text{mol/L}$  EdU. Representative images are shown; two-tailed *t*-test was used. Data are expressed as means  $\pm$  SEM (**B** and **C**). Error bars represent SDs (**A**).  $n = 5$  (**E**).  $*P < 0.05$  versus *miR-LacZ* (two-tailed *t*-test). Scale bars = 200  $\mu\text{m}$  (**B**). Original magnification:  $\times 10$  (**C**);  $\times 20$  (**D**).

also demonstrated that *miR-431* down-regulated an epithelial marker, *CDH1*, and up-regulated mesenchymal markers, including *CDH2*, *SIP1*, and *SLUG* (Figure 3E). In addition, Western blot analysis showed down-regulation of cadherin 1 and up-regulation of Slug in *GFP-miR-431*-expressing N134 cells compared with *GFP-miR-LacZ*-expressing N134 cells (Figure 3C). Taken together, the results of RNA-Seq, Western blot analysis, and RPPA revealed the function of *GFP-miR-431* in increasing Ras/Erk signaling and inducing EMT of PNET cells.

To determine whether Erk signaling plays a role for PNET cell invasion, N134/*GFP-miR-431* cells were treated with an Erk inhibitor, SCH772984, or dimethyl sulfoxide vehicle control; and the effect on cell invasion was measured using transwell invasion assay. SCH772984 greatly reduced p-Erk levels (Figure 4A) and reduced cell invasion (Figure 4B), suggesting that active Erk signaling is required for PNET cell invasion.


#### *miR-431* Directly Targets DAB2IP, a RasGAP

The mature sequence of *miR-431* (5'-UGU-CUUGCAGGCCGUCAUGCA-3') is identical among human, rat, and mouse (Figure 5A). To identify mRNA targets of *miR-431*, four target prediction modules, including miRWalk,<sup>34</sup> miRnada,<sup>35</sup> RNA22,<sup>36</sup> and Targetscan, were searched.<sup>37</sup> The putative *miR-431* target genes that were predicted by at least three modules and showed an

**Table 2** Impact of *miR-431* Overexpression on Experimental Metastasis *in Vivo*

N134 cells	Liver metastases
<i>GFP-miR-LacZ</i>	2/7 mice (28.6%)
<i>GFP-miR-431</i>	6/6 mice (100%)*

\* $P < 0.05$  (Fisher exact test).



**Figure 3** *miR-431* activates Erk and EMT. **A:** RNA-sequencing (RNA-Seq) and gene set enrichment analysis shows a correlation between *miR-431* expression and KRAS signature in N134 cells. **B:** Cell lysates were prepared from N134/*GFP-miR-LacZ* and N134/*GFP-miR-431* and a human pancreatic ductal adenocarcinoma cell line, AsPC1. Western blot analysis shows precipitated active Ras protein, total Ras, phosphorylated extracellular signal-regulated kinase 1/2 (p-Erk1/2), and total Erk1/2 (t-Erk1/2). The intensity of the Ras protein bands was quantified and normalized (Norm.) to the Ras bands in the N134/*GFP-miR-LacZ* cells. **C:** Western blot analysis for p-Erk1/2, total Erk1/2, cadherin 1, Slug, and tubulin. **D:** RNA-Seq analysis in fragments per kilobase of transcript per million mapped reads (FPKM) reveals up-regulation of mesenchymal markers, *CDH2*, *ZEB2*, and *SNAI2*, in N134/*GFP-miR-431* cells compared with those in the control N134/*GFP-miR-LacZ* cells. *t*-Test was used. **E:** Real-time PCR analysis of *CDH1*, *CDH2*, *ZEB2*, and *SNAI2* mRNAs in N134/*GFP-miR-LacZ* and N134/*GFP-miR-431* cells. Two-tailed *t*-test was used. Data are expressed as means  $\pm$  SEM (**D** and **E**).  $n = 7$  independent experiments (**E**). \* $P < 0.05$  versus *miR-LacZ*. NES, normalized enrichment score.

inverse correlation with *miR-431* expression in the RNA-Seq described above were selected. This approach identified 202 potential *miR-431* target genes (Figure 5B and Supplemental Table S1). They were subjected to DAVID gene-enrichment and functional annotation analysis.

**Table 3** Protein Up-Regulated in N134/*GFP-miR-431* Cells Compared with N134/*GFP-miR-LacZ* Cells in RPPA Analysis

Protein name	Fold change ( <i>miR-431</i> vs <i>miR-LacZ</i> )	Adjusted <i>P</i> value
p-Erk1/2 (T202/Y204)	5.20	0.031
Slug	1.72	0.000
Cadherin 2	1.70	0.015
PKM1/2	1.31	0.004
p-FAK (Y576/577)	1.30	0.004
p-Stat3 (S727)	1.29	0.004
Sin3b	1.24	0.018
Stat6	1.23	0.007
Ezh2	1.19	0.007
Erk1/2	1.17	0.047


Erk1/2, extracellular signal-regulated kinase 1/2; p-Erk1/2, phosphorylated Erk1/2; RPPA, reverse phase protein array.

Functional annotation clustering showed enrichment of GTPase activator activity among the top three clusters (Supplemental Table S2). *DAB2IP* was identified as the top potential target of *miR-431* in PNETs (Figure 5, B and C).

*DAB2IP* is a RasGAP, and it acts as a tumor suppressor gene in prostate cancer.<sup>22</sup> The mRNA expression of *DAB2IP* was down-regulated [ $\log_2$  (fold change) =  $-0.427264$ ] in *GFP-miR-431*-expressing N134 cells compared with *GFP-miR-LacZ*-expressing N134 cells in the above RNA-Seq analysis (Figure 5D). *DAB2IP* protein levels were also down-regulated in *GFP-miR-431*-expressing N134 cells compared with control *GFP-miR-LacZ*-expressing N134 cells (Figure 5E).

To validate whether *DAB2IP* is a direct target of *miR-431*, a luciferase reporter construct containing a partial sequence of the *DAB2IP* 3' UTR encompassing the *miR-431* site was used. Wild-type or mutant 3' UTR of mouse *DAB2IP* (Figure 5C) was cloned into a pmirGLO dual-luciferase miRNA target expression vector. Unexpectedly, a putative *miR-431* target sequence was found in pmirGLO vector, so cotransfection of *miR-431* reduced the luciferase activity of the control pmirGLO vector compared with







**Figure 4** Extracellular signal-regulated kinase (Erk) inhibition suppresses invasion induced by *miR-431* *in vitro*. **A:** Western blot analysis for phosphorylated Erk1/2 (p-Erk1/2) and total Erk1/2 (t-Erk1/2) in N134/*GFP-miR-LacZ* and N134/*GFP-miR-431* cells treated with dimethyl sulfoxide (DMSO; vehicle control) or SCH772984 (SCH). **B:** Invasion of cells pretreated with DMSO (vehicle control) or SCH772984 (1  $\mu\text{mol/L}$ ) using *in vitro* Matrigel invasion chambers with a serum gradient (1% to 10%). Data are expressed as the normalized number of invaded cells in the bottom surface of chambers in eight fields under  $\times 10$  magnification after 48 hours relative to that of vehicle treated control cells. Data are expressed as means  $\pm$  SEM (**B**). \* $P < 0.05$  (two-tailed *t*-test). Scale bars = 200  $\mu\text{m}$  (**B**).

cotransfection of scrambled miRNA control (Figure 5F). Cotransfection of *miR-431* and the vector carrying wild-type 3' UTR of mouse *DAB2IP* further repressed the luciferase activity in 293T cells (Figure 5F). Consistent with its direct targeting, mutating the *miR-431-5p* complementary seed region (Figure 5C) on the 3' UTR of *DAB2IP* abrogated miRNA-mediated regulation (Figure 5F).

Moreover, the luciferase reporter–based activity assay was performed in human PNET QGP1 cell line with its endogenous *miR-431*. The pmirGLO vector, the vector carrying wild-type 3' UTR of *DAB2IP*, or the vector carrying mutant 3' UTR was transfected to QGP1 cells, and their luciferase activities were measured. Consistent with the cotransfection results in 293T cells, luciferase reporter



**Figure 5** *miR-431* directly targets *DAB2IP*. **A:** Sequence alignment of *miR-431* from human, rat, and mouse. Asterisks indicate identical nucleotides. **B:** *miR-431* target sequence and the potential binding site at the 3' untranslated region (UTR) of mouse *DAB2IP*. *DAB2IP* 3' UTR mutant (Mut) indicates the mutated sites in the seeding sequence. **C:** Alignment of *miR-431* targeting sequence (red: seed region) in *DAB2IP* 3' UTR and the sequence of Mut *DAB2IP* 3' UTR. **D:** *DAB2IP* expression was measured by RNA sequencing in fragments per kilobase of transcript per million mapped reads (FPKM). \*\* $q = 0.004$ ,  $q$  values represent false discovery rate—adjusted  $P$  values outputted by Cuffdiff. **E:** Western blot analysis for *DAB2IP* to demonstrate the repression of *DAB2IP* in N134/*GFP-miR-431* cells. **F:** Dual-luciferase assays of pmirGLO or wild-type (WT) 3' UTR or 3' UTR Mut of *DAB2IP* after cotransfection with *miR-431* mimic or scrambled miRNA. **G:** Dual-luciferase assays after transfection with pmirGLO or *DAB2IP* WT 3' UTR or 3' UTR Mut in QGP1 cells. **F** and **G:** Normalized firefly luciferase activity (firefly luciferase activity/ Renilla luciferase activity) for each construct was compared with that of the pmirGLO vector no-insert control. Three independent measurements were performed. Data are expressed as means  $\pm$  SEM (**D**, **F**, and **G**). \*\* $P < 0.01$  versus miR-LacZ; †† $P < 0.01$ ; ††† $P < 0.01$  versus vector alone or the mutant 3' UTR of *DAB2IP*.



**Figure 6** Expression of human DAB2IP and rat homolog blocks the invasiveness effect of *miR-431*, and *miR-431* inhibition suppresses invasion of human pancreatic neuroendocrine tumor (PNET) cells. **A**: Invasion of N134/*GFP-miR-431* expressing a control vector (pCI-neo), rat DAB2IP or GTPase activating protein (GAP) mutant of DAB2IP was determined using *in vitro* Matrigel invasion chamber with a serum gradient (1% to 10%). Forty-eight hours after transfection of DNA, cells were trypsinized and  $10^6$  cells were seeded onto Matrigel invasion chamber. After 72 hours of incubation, cells on the opposite side of the chambers were fixed, stained, and counted. Experiment was conducted in triplicate. Data are expressed as the normalized number of invaded cells in the bottom surface of chambers in all fields under  $\times 20$  magnification. **B**: Proliferation of N134/*GFP-miR-431* expressing a control vector (pCI-neo), rat DAB2IP or GAP mutant was compared. **C**: Western blot analysis for rat DAB2IP using DAB2IP antibodies, phosphorylated extracellular signal-regulated kinase 1/2 (p-Erk1/2), total Erk1/2 (t-Erk1/2), E-cadherin, and Slug in N134/*GFP-miR-431* cells expressing a control vector (pCI-neo), rat DAB2IP, or GAP mutant. **D**: Expression levels of *miR-431*, determined by TaqMan miRNA expression assay, in three human pancreatic ductal adenocarcinoma (PDAC) cell lines and two human PNET cell lines. **E**: Invasion of human PNET cells (QGP1) treated with a control inhibitor (LNA-CTRL) or a *miR-431* inhibitor (LNA-*miR-431*) was determined using *in vitro* Matrigel invasion chambers with a serum gradient (1% to 10%). **F**: Western blot analysis for DAB2IP and tubulin in human PNET cells (QGP1) treated with control inhibitor (LNA-CTRL) or *miR-431* inhibitor (LNA-*miR-431*). **G**: Model depicting the mechanism by which *miR-431* promotes metastasis of PNETs. Data are expressed as means  $\pm$  SEM (A, B, D, and E).  $n = 5$  (E). \* $P < 0.05$  versus Panc1, MIA Paca-2, and BxPC3 (two-tailed *t*-test); † $P < 0.05$  versus LNA-CTRL (two-tailed *t*-test). Scale bars = 200  $\mu$ m (E). EMT, epithelial-mesenchymal transition; GEF, guanine nucleotide exchange factor.

activity of wild-type 3' UTR of *DAB2IP* was significantly lower than that of the vector alone or the mutant 3' UTR of *DAB2IP* (Figure 5G). Taken together, these findings established *DAB2IP* as a direct target of miR-431.

### GAP Activity of *DAB2IP* Interferes with the Metastatic Function of *miR-431*

*DAB2IP* protein identity is >80% among human, rat, and mouse. To determine whether the metastatic function of *miR-431* is mediated by targeting *DAB2IP*, rat *DAB2IP* homolog, or a mutant defective in its GAP activity<sup>22,38</sup> was expressed in N134/*GFP-miR-431* cells. Both of cDNAs did not have the 3' UTR binding site of *miR-431* and therefore could not be down-regulated by *miR-431* (*miR-431* resistant). Overexpression of *miR-431*-resistant rat *DAB2IP* cDNA reversed the invasive effect of *miR-431* without affecting cell proliferation (Figure 6, A and B). Moreover, *miR-431*-resistant rat *DAB2IP* reduced p-Erk and Slug levels and increased cadherin 1 (Figure 6C). These effects required the GAP activity, because overexpression of the GAP mutant in N134 cells expressing *GFP-miR-431* did not sufficiently inhibit cell invasion, reduce p-Erk, or block EMT (Figure 6, A–C). The data suggested that the GAP activity of *DAB2IP* is important to inhibit PNET invasion.

### *miR-431* as a Therapeutic Target in PNET Metastasis

By real-time PCR, it was found that two human PNET cell lines, BON1 and QGP1, expressed higher endogenous *miR-431* levels than three human PDAC cell lines, Panc1, MIA Paca-2, and BxPC3 (Figure 6D). Especially, QGP1 had the highest endogenous *miR-431* levels among these five cell lines (Figure 6D). Consistent with our findings that *DAB2IP* is a direct target of *miR-431* in pancreatic cancer cells, Western blot analysis showed an inverse correlation between the expression levels of *miR-431* and the *DAB2IP* protein levels in these five human PDAC and PNET cell lines (Figure 6D).

To determine therapeutic value of targeting *miR-431*, QGP1 cells were treated with antisense locked nucleic acids (LNAs).<sup>39</sup> LNAs sequester their target miRNAs in highly stable heteroduplexes, thereby effectively preventing the miRNA from hybridizing with its normal cellular targets. Transfection of an LNA inhibitor for human *miR-431-5p* significantly inhibited invasiveness of QGP1 compared with transfection of a control LNA (Figure 6E), restored the expression of *DAB2IP*, and down-regulated Erk signaling (Figure 6F).

## Discussion

The incidence of PNETs is increasing in recent years. Because of the indolent nature of the disease, most PNET patients are diagnosed with liver metastasis. The drivers of metastatic PNETs are largely unknown, which makes the

development of treatment difficult. Through a cross-species analysis in human PNETs and mouse PNETs in *RIP-Tag* mouse models, a metastatic-specific miRNA signature has been revealed.<sup>11</sup> *miR-431* is the most up-regulated miRNA in this signature. The function of *miR-431* in tumorigenesis appears to be context dependent. *miR-431* acts as tumor suppressor in colorectal cancer cells and hepatocellular carcinoma. It inhibits migration of colorectal cancer cells and hepatocellular carcinoma cells.<sup>40,41</sup> In contrast, *miR-431* demonstrated promoted migration and invasion of PNET *in vitro*, and metastasis in both spontaneous PNET and experimental metastasis mouse models, suggesting its oncogenic role in PNETs. The disparity of *miR-431* functions could be because of the availability of its targets in different cancer types. Further studies are needed to address this possibility.

Although oncogenic *KRAS* is found in nearly every PDAC to drive tumorigenesis,<sup>42,43</sup> *KRAS* mutations are virtually nonexistent in PNETs.<sup>44</sup> On the other hand, *miR-431* overexpression is not detected in PDAC,<sup>45</sup> suggesting that the two mechanisms are redundant and likely mutually exclusive in pancreatic tumorigenesis. This study demonstrated that metastatic PNETs up-regulated *miR-431* to activate the Ras/Erk pathway through targeting *DAB2IP*. Our study suggested that the Ras signaling pathway is also important in PNET progression. *DAB2IP*, a RasGAP, negatively controls Ras-dependent mitogenic signals.<sup>46</sup> *DAB2IP* has recently been found significantly down-regulated in multiple types of cancer,<sup>47</sup> including prostate cancer,<sup>48</sup> breast cancer,<sup>49,50</sup> colon cancer,<sup>51</sup> and bladder cancer.<sup>52</sup> Down-regulation of *DAB2IP* has been shown to promote prostate cancer progression<sup>53</sup> and colorectal cancer invasion and metastasis.<sup>51</sup> The aberrant alteration of *DAB2IP* in cancer is caused by a variety of mechanisms, including targeted by miRNAs, aberrant promoter methylation, histone deacetylation, and others. Herein, it was shown that *DAB2IP* suppression plays an oncogenic role in PNET metastasis. It requires further scrutiny to determine the frequency of human metastatic PNET with down-regulation of *DAB2IP*.

Given the ability of miRNAs to target multiple genes, they are appealing therapeutic agents.<sup>54</sup> The therapeutic strategies either blocking oncogenic miRNAs or introducing tumor suppressor miRNAs have developed rapidly in recent years.<sup>55</sup> It is proposed that targeting *miR-431* may be a novel therapeutic strategy for PNETs. Besides RasGAPs, genes involved in zinc transport were among the top putative *miR-431* target genes in PNETs from our analysis (Supplemental Table S2). Zinc is an essential micronutrient that plays a role in the functions of many cellular proteins, and zinc is emerging as an important signaling molecule in the progression of cancer. Further studies are required to investigate whether these candidates are *miR-431* targets and whether zinc dyshomeostasis contributes to PNET metastasis.

In summary, we have identified that overexpression of *miR-431* promotes PNET cell migration and invasion

*in vitro* and metastasis in both spontaneous and xenograft mouse models of PNETs (Figure 6G). *miR-431* directly silenced RasGAP tumor suppressor, *DAB2IP*. Down-regulation of *DAB2IP* led to the activation of Ras/Erk signaling, EMT, and cell invasion.

## Acknowledgments

We thank Drs. Inna Serganova and Ronald Blasberg for viruses carrying thymidine kinase/green fluorescent protein/luciferase fusion reporter; Jason T. Huse for RCASBP constructs for miRNA expression; Jer-Tsong Hsieh for DAB2 interacting protein (DAB2IP) antibodies, DAB2IP plasmids, and discussion; Chris Harris for QGPI cell line; Andrea Ventura, Yi Li, Pengbo Zhou, and Irene Min for advice; Danny Huang for mouse database design; George Zhang, Megan Wong, and Joseph Na for mouse colony management; Kimal Rajapakshe and Cristian Coarfa for reverse phase protein array (RPPA) data processing and normalization; and Fuli Jia and Danli Wu (Antibody-Based Proteomics Core/Shared Resource) for excellent technical assistance in performing RPPA experiments.

## Author Contributions

T.Z., S.C., and Y.C., designed and performed the experiments and analyzed the data; T.Z. contributed to bioinformatics analysis; Z.C. performed statistical analysis; S.H. directed reverse phase protein array; J.Z.X. directed RNA sequencing; Y.C.N.D. designed the experiments, analyzed the data, and wrote the manuscript.

## Supplemental Data

Supplemental material for this article can be found at <https://doi.org/10.1016/j.ajpath.2019.11.007>.

## References

- Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A: Exocrine and endocrine pancreas. *AJCC Cancer Staging Manual*. ed 7. New York, NY, Springer-Verlag, 2010. pp. 241–249
- Zhang JFR, Iyer R, Seshadri M, Zajac-Kaye M, Hochwald SN: Current understanding of the molecular biology of pancreatic neuroendocrine tumors. *J Natl Cancer Inst* 2013, 105:1005–1017
- Buicko JL, Finnerty BM, Zhang T, Kim BJ, Fahey TJ 3rd, Du YC: Insights into the biology and treatment strategies of pancreatic neuroendocrine tumors. *Ann Pancreat Cancer* 2019, 2:12
- Blumenthal GMCP, Zhang JJ, Tang S, Sridhara R, Murgo A, Justice R, Pazdur R: FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors. *Oncologist* 2012, 17: 1108–1113
- Cives M, Strosberg J: Radionuclide therapy for neuroendocrine tumors. *Curr Oncol Rep* 2017, 19:9
- Yao JCSM, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Leubwohl D, Öberg K: Everolimus for advanced pancreatic neuroendocrine tumors. *N Engl J Med* 2011, 364:514–523
- Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC: Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. *JAMA Oncol* 2017, 3:1335–1342
- Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell* 2004, 116:281–297
- Ma L, Teruya-Feldstein J, Weinberg RA: Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. *Nature* 2007, 449:682–688
- Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD, Gerald WL, Massague J: Endogenous human microRNAs that suppress breast cancer metastasis. *Nature* 2008, 451:147–152
- Olson P, Lu J, Zhang H, Shai A, Chun MG, Wang Y, Libutti SK, Nakakura EK, Golub TR, Hanahan D: MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. *Genes Dev* 2009, 23:2152–2165
- Sadanandam A, Wullschlegel S, Lyssiotis CA, Grotzinger C, Barbi S, Bersani S, Korner J, Wafy I, Mafficini A, Lawlor RT, Simbolo M, Asara JM, Blaker H, Cantley LC, Wiedenmann B, Scarpa A, Hanahan D: A cross-species analysis in pancreatic neuroendocrine tumors reveals molecular subtypes with distinctive clinical, metastatic, developmental, and metabolic characteristics. *Cancer Discov* 2015, 5:1296–1313
- Loftus SK, Larson DM, Watkins-Chow D, Church DM, Pavan WJ: Generation of RCAS vectors useful for functional genomic analyses. *DNA Res* 2001, 8:221–226
- Huse JT, Brennan C, Hambarzumyan D, Wee B, Pena J, Rouhanifard SH, Sohn-Lee C, le Sage C, Agami R, Tuschl T, Holland EC: The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis *in vivo*. *Genes Dev* 2009, 23:1327–1337
- Himly M, Foster DN, Bottoli I, Iacovoni JS, Vogt PK: The DF-1 chicken fibroblast cell line: transformation induced by diverse oncogenes and cell death resulting from infection by avian leukosis viruses. *Virology* 1998, 248:295–304
- Schaefer-Klein J, Givol I, Barsov EV, Whitcomb JM, VanBrocklin M, Foster DN, Federspiel MJ, Hughes SH: The EV-O-derived cell line DF-1 supports the efficient replication of avian leukosis-sarcoma viruses and vectors. *Virology* 1998, 248: 305–311
- Du YC, Lewis BC, Hanahan D, Varmus H: Assessing tumor progression factors by somatic gene transfer into a mouse model: Bcl-xL promotes islet tumor cell invasion. *PLoS Biol* 2007, 5:e276
- Zhang G, Chi Y, Du YC: Identification and characterization of metastatic factors by gene transfer into the novel RIP-Tag; RIP-tva Murine model. *J Vis Exp* 2017, 128:55890
- Tang LH, Contractor T, Clausen R, Klimstra DS, Du YC, Allen PJ, Brennan MF, Levine AJ, Harris CR: Attenuation of the retinoblastoma pathway in pancreatic neuroendocrine tumors due to increased *cdk4/cdk6*. *Clin Cancer Res* 2012, 18:4612–4620
- Evers BM, Townsend CM Jr, Upp JR, Allen E, Hurlbut SC, Kim SW, Rajaraman S, Singh P, Reubi JC, Thompson JC: Establishment and characterization of a human carcinoid in nude mice and effect of various agents on tumor growth. *Gastroenterology* 1991, 101: 303–311
- Ponomarev V, Doubrovin M, Serganova I, Vider J, Shavrin A, Beresten T, Ivanova A, Ageyeva L, Tourkova V, Balatoni J, Bornmann W, Blasberg R, Gelovani Tjuvaje J: A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging. *Eur J Nucl Med Mol Imaging* 2004, 31:740–751
- Wang Z, Tseng CP, Pong RC, Chen H, McConnell JD, Navone N, Hsieh JT: The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer: characterization of a novel

- GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2. *J Biol Chem* 2002, 277:12622–12631
23. Choi S, Chen Z, Tang LH, Fang Y, Shin SJ, Panarelli NC, Chen YT, Li Y, Jiang X, Du YC: Bcl-xL promotes metastasis independent of its anti-apoptotic activity. *Nat Commun* 2016, 7:10384
  24. Kim D, Perete G, Trapnell C, Pimentel H, Kelley R, Salzberg SL: TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. *Genome Biol* 2013, 14:R36
  25. Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, Salzberg SL, Wold BJ, Pachter L: Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. *Nat Biotechnol* 2010, 28:511–515
  26. Trapnell C, Hendrickson DG, Sauvageau M, Goff L, Rinn JL, Pachter L: Differential analysis of gene regulation at transcript resolution with RNA-seq. *Nat Biotechnol* 2013, 31:46–53
  27. Chang CH, Zhang M, Rajapakse K, Coarfa C, Edwards D, Huang S, Rosen JM: Mammary stem cells and tumor-initiating cells are more resistant to apoptosis and exhibit increased DNA repair activity in response to DNA damage. *Stem Cell Reports* 2015, 5:378–391
  28. Creighton CJ, Huang S: Reverse phase protein arrays in signaling pathways: a data integration perspective. *Drug Des Devel Ther* 2015, 9:3519–3527
  29. Holdman XB, Welte T, Rajapakse K, Pond A, Coarfa C, Mo Q, Huang S, Hilsenbeck SG, Edwards DP, Zhang X, Rosen JM: Upregulation of EGFR signaling is correlated with tumor stroma remodeling and tumor recurrence in FGFR1-driven breast cancer. *Breast Cancer Res* 2015, 17:141
  30. Welte T, Kim IS, Tian L, Gao X, Wang H, Li J, Holdman XB, Herschkowitz JI, Pond A, Xie G, Kurley S, Nguyen T, Liao L, Dobrolecki LE, Pang L, Mo Q, Edwards DP, Huang S, Xin L, Xu J, Li Y, Lewis MT, Wang T, Westbrook TF, Rosen JM, Zhang XH: Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation. *Nat Cell Biol* 2016, 18:632–644
  31. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK: limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res* 2015, 43:e47
  32. Deer EL, Gonzalez-Hernandez J, Coursen JD, Shea JE, Ngatia J, Scaife CL, Firpo MA, Mulvihill SJ: Phenotype and genotype of pancreatic cancer cell lines. *Pancreas* 2010, 39:425–435
  33. Shin S, Dimitri CA, Yoon SO, Dowdle W, Blenis J: ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events. *Mol Cell* 2010, 38:114–127
  34. Dweep H, Sticht C, Pandey P, Gretz N: miRWalk-database: prediction of possible miRNA binding sites by “walking” the genes of three genomes. *J Biomed Inform* 2011, 44:839–847
  35. John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS: Human microRNA targets. *PLoS Biol* 2004, 2:e363
  36. Miranda KC, Huynh T, Tay Y, Ang YS, Tam WL, Thomson AM, Lim B, Rigoutsos I: A pattern-based method for the identification of microRNA binding sites and their corresponding heteroduplexes. *Cell* 2006, 126:1203–1217
  37. Agarwal V, Bell GW, Nam JW, Bartel DP: Predicting effective microRNA target sites in mammalian mRNAs. *eLife* 2015, 4:e05005
  38. Chen H, Karam JA, Schultz R, Zhang Z, Duncan C, Hsieh JT: Cloning of mouse Dab2ip gene, a novel member of the RasGTPase-activating protein family and characterization of its regulatory region in prostate. *DNA Cell Biol* 2006, 25:232–245
  39. Elmen J, Lindow M, Schutz S, Lawrence M, Petri A, Obad S, Lindholm M, Hedtjarn M, Hansen HF, Berger U, Gullans S, Kearney P, Sarnow P, Straarup EM, Kauppinen S: LNA-mediated microRNA silencing in non-human primates. *Nature* 2008, 452:896–899
  40. Su WB, Liu ZY: MiR-431 inhibits colorectal cancer cell invasion via repressing CUL4B. *Eur Rev Med Pharmacol Sci* 2018, 22:3047–3052
  41. Sun K, Zeng T, Huang D, Liu Z, Huang S, Liu J, Qu Z: MicroRNA-431 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the ZEB1-mediated epithelial-mesenchymal transition. *FEBS Open Bio* 2015, 5:900–907
  42. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M: Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. *Cell* 1988, 53:549–554
  43. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA, Kawaguchi Y, Johann D, Liotta LA, Crawford HC, Putt ME, Jacks T, Wright CV, Hruban RH, Lowy AM, Tuveson DA: Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. *Cancer Cell* 2003, 4:437–450
  44. Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schlick RD, Tang LH, Wolfgang CL, Choti MA, Velculescu VE, Diaz LA Jr, Vogelstein B, Kinzler KW, Hruban RH, Papadopoulos N: DAXX/ATRAX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. *Science* 2011, 331:1199–1203
  45. Tesfaye AA, Azmi AS, Philip PA: miRNA and gene expression in pancreatic ductal adenocarcinoma. *Am J Pathol* 2019, 189:58–70
  46. Bellazzo A, Di Minin G, Collavin L: Block one, unleash a hundred: mechanisms of DAB2IP inactivation in cancer. *Cell Death Differ* 2017, 24:15–25
  47. Liu L, Xu C, Hsieh JT, Gong J, Xie D: DAB2IP in cancer. *Oncotarget* 2016, 7:3766–3776
  48. Chen H, Pong RC, Wang Z, Hsieh JT: Differential regulation of the human gene DAB2IP in normal and malignant prostatic epithelia: cloning and characterization. *Genomics* 2002, 79:573–581
  49. Olsen SN, Wronski A, Castano Z, Dake B, Malone C, De Raedt T, Enos M, DeRose YS, Zhou W, Guerra S, Loda M, Welm A, Partridge AH, McAllister SS, Kuperwasser C, Cichowski K: Loss of RasGAP tumor suppressors underlies the aggressive nature of luminal B breast cancers. *Cancer Discov* 2017, 7:202–217
  50. Dote H, Toyooka S, Tsukuda K, Yano M, Ouchida M, Doihara H, Suzuki M, Chen H, Hsieh JT, Gazdar AF, Shimizu N: Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in breast cancer. *Clin Cancer Res* 2004, 10:2082–2089
  51. Zhu XH, Wang JM, Yang SS, Wang FF, Hu JL, Xin SN, Men H, Lu GF, Lan XL, Zhang D, Wang XY, Liao WT, Ding YQ, Liang L: Down-regulation of DAB2IP promotes colorectal cancer invasion and metastasis by translocating hnRNPK into nucleus to enhance the transcription of MMP2. *Int J Cancer* 2017, 141:172–183
  52. Feng C, Sun P, Hu J, Feng H, Li M, Liu G, Pan Y, Feng Y, Xu Y, Feng K, Feng Y: miRNA-556-3p promotes human bladder cancer proliferation, migration and invasion by negatively regulating DAB2IP expression. *Int J Oncol* 2017, 50:2101–2112
  53. Wu K, Liu J, Tseng SF, Gore C, Ning Z, Sharifi N, Fazli L, Gleave M, Kapur P, Xiao G, Sun X, Oz OK, Min W, Alexandrakis G, Yang CR, Hsieh CL, Wu HC, He D, Xie D, Hsieh JT: The role of DAB2IP in androgen receptor activation during prostate cancer progression. *Oncogene* 2014, 33:1954–1963
  54. Garzon R, Marcucci G, Croce CM: Targeting microRNAs in cancer: rationale, strategies and challenges. *Nat Rev Drug Discov* 2010, 9:775–789
  55. Ji W, Sun B, Su C: Targeting microRNAs in cancer gene therapy. *Genes (Basel)* 2017, 8:21